谷氨酰胺
肝细胞癌
新陈代谢
癌症研究
细胞内
肿瘤微环境
化学
转录组
细胞生物学
串扰
细胞
运输机
重编程
生物
代谢途径
肿瘤进展
细胞培养
细胞生长
细胞代谢
表型
谷氨酰胺合成酶
生物化学
下调和上调
核糖核酸
碳水化合物代谢
癌细胞
体外
程序性细胞死亡
信号转导
细胞凋亡
外周血单个核细胞
谷氨酰胺分解
作者
Yujing Guo,Qian Huang,Sha Yin,Lunbiao Gan,Zehua Liu,Jiaqi Ning,Yu Lu,Wenxiu Ru,Fengze Nie,Sijia Di,Siyu Yao,Huanhuan Wan,Le Liu,Fa Yang,Weijun Qin,Weihong Wen
摘要
ABSTRACT Hepatocellular carcinoma (HCC) is the third leading cause of cancer‐related deaths globally. Current therapeutic options remain limited by poor efficacy, and there is an urgent need to identify new therapeutic targets and strategies. Metabolic reprogramming is a hallmark of HCC progression, and intercellular crosstalk within the tumor microenvironment (TME) critically shapes tumor cell metabolism. However, the cell types and mechanisms regulating HCC cell metabolism remain largely unclear. In this study, by combining single‐cell RNA sequencing (scRNA‐seq) and spatial transcriptomic data, we found that M2‐like tumor‐associated macrophages (TAMs) were associated with highly metabolic HCC cells. Using intercellular protein interaction detection (ICPID), a proximity‐labeling method developed in this study, we identified that Galectin‐9 (Gal‐9), highly expressed and secreted by M2 macrophages, is a ligand for the glutamine transporter SLC1A5 on HCC cells. This glycan‐dependent interaction promoted the membrane localization of SLC1A5, thereby enhancing glutamine uptake and metabolism to promote HCC growth. Gal‐9 neutralization or SLC1A5 inhibition suppressed glutamine metabolism and tumor‐promoting phenotypes both in vitro and in vivo. Our study shows that M2 macrophage‐derived Gal‐9 can promote HCC progression by directly enhancing glutamine metabolism in HCC cells, and that the Gal‐9‐SLC1A5 axis may serve as a new therapeutic target for HCC treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI